IgEs targeted on tumor cells: Therapeutic activity and potential in the design of tumor vaccines

E. Reali, J. W. Greiner, A. Corti, H. J. Gould, F. Bottazzoli, G. Paganelli, J. Schlom, A. G. Siccardi

Research output: Contribution to journalArticle

Abstract

Surface-bound IgE play a central role in antiparasite immunity; to exploit IgE-driven immune mechanisms in tumor prevention and control, monoclonal IgEs of irrelevant specificity were loaded through biotin-avidin bridging onto tumor cells, either by systemic administration to tumor-bearing mice or pre-loading of tumor cells before inoculation. Here we show that systemic administration of biotinylated IgEs to mice bearing tumors pre-targeted with biotinylated antibodies and avidin significantly decreased tumor growth rate. In addition, as compared with IgG-loaded control cells, inoculation of suboptimal doses of IgE-loaded tumor cells suppressed tumor formation in a fraction of animals and induced protective host immunity by eliciting tumor-specific T-cell responses. Similarly, tumor vaccination experiments showed that irradiated tumor cells (IgE loaded by biotin-avidin bridging) conferred protective immunity at doses 100-fold lower than the corresponding control cells without IgE. Finally, in vivo depletion of eosinophils or T cells abrogated IgE-driven tumor growth inhibition. These results demonstrate that IgEs targeted on tumor cells not only possess a curative potential but also confer long-term antitumor immunity and that IgE-driven antitumor activity is not restricted to the activation of innate immunity effector mechanisms but also results from eosinophil-dependent priming of a T-cell-mediated adaptive immune response. This suggests a potential role for IgEs in the design of new cell-based tumor vaccines.

Original languageEnglish
Pages (from-to)5517-5522
Number of pages6
JournalCancer Research
Volume61
Issue number14
Publication statusPublished - Jul 15 2001

Fingerprint

Cancer Vaccines
Immunoglobulin E
Neoplasms
Avidin
Therapeutics
Immunity
Biotin
T-Lymphocytes
Eosinophils
Adaptive Immunity
Growth
Innate Immunity
Vaccination

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Reali, E., Greiner, J. W., Corti, A., Gould, H. J., Bottazzoli, F., Paganelli, G., ... Siccardi, A. G. (2001). IgEs targeted on tumor cells: Therapeutic activity and potential in the design of tumor vaccines. Cancer Research, 61(14), 5517-5522.

IgEs targeted on tumor cells : Therapeutic activity and potential in the design of tumor vaccines. / Reali, E.; Greiner, J. W.; Corti, A.; Gould, H. J.; Bottazzoli, F.; Paganelli, G.; Schlom, J.; Siccardi, A. G.

In: Cancer Research, Vol. 61, No. 14, 15.07.2001, p. 5517-5522.

Research output: Contribution to journalArticle

Reali, E, Greiner, JW, Corti, A, Gould, HJ, Bottazzoli, F, Paganelli, G, Schlom, J & Siccardi, AG 2001, 'IgEs targeted on tumor cells: Therapeutic activity and potential in the design of tumor vaccines', Cancer Research, vol. 61, no. 14, pp. 5517-5522.
Reali, E. ; Greiner, J. W. ; Corti, A. ; Gould, H. J. ; Bottazzoli, F. ; Paganelli, G. ; Schlom, J. ; Siccardi, A. G. / IgEs targeted on tumor cells : Therapeutic activity and potential in the design of tumor vaccines. In: Cancer Research. 2001 ; Vol. 61, No. 14. pp. 5517-5522.
@article{226400ac40c8483184815fa04e2008c2,
title = "IgEs targeted on tumor cells: Therapeutic activity and potential in the design of tumor vaccines",
abstract = "Surface-bound IgE play a central role in antiparasite immunity; to exploit IgE-driven immune mechanisms in tumor prevention and control, monoclonal IgEs of irrelevant specificity were loaded through biotin-avidin bridging onto tumor cells, either by systemic administration to tumor-bearing mice or pre-loading of tumor cells before inoculation. Here we show that systemic administration of biotinylated IgEs to mice bearing tumors pre-targeted with biotinylated antibodies and avidin significantly decreased tumor growth rate. In addition, as compared with IgG-loaded control cells, inoculation of suboptimal doses of IgE-loaded tumor cells suppressed tumor formation in a fraction of animals and induced protective host immunity by eliciting tumor-specific T-cell responses. Similarly, tumor vaccination experiments showed that irradiated tumor cells (IgE loaded by biotin-avidin bridging) conferred protective immunity at doses 100-fold lower than the corresponding control cells without IgE. Finally, in vivo depletion of eosinophils or T cells abrogated IgE-driven tumor growth inhibition. These results demonstrate that IgEs targeted on tumor cells not only possess a curative potential but also confer long-term antitumor immunity and that IgE-driven antitumor activity is not restricted to the activation of innate immunity effector mechanisms but also results from eosinophil-dependent priming of a T-cell-mediated adaptive immune response. This suggests a potential role for IgEs in the design of new cell-based tumor vaccines.",
author = "E. Reali and Greiner, {J. W.} and A. Corti and Gould, {H. J.} and F. Bottazzoli and G. Paganelli and J. Schlom and Siccardi, {A. G.}",
year = "2001",
month = "7",
day = "15",
language = "English",
volume = "61",
pages = "5517--5522",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - IgEs targeted on tumor cells

T2 - Therapeutic activity and potential in the design of tumor vaccines

AU - Reali, E.

AU - Greiner, J. W.

AU - Corti, A.

AU - Gould, H. J.

AU - Bottazzoli, F.

AU - Paganelli, G.

AU - Schlom, J.

AU - Siccardi, A. G.

PY - 2001/7/15

Y1 - 2001/7/15

N2 - Surface-bound IgE play a central role in antiparasite immunity; to exploit IgE-driven immune mechanisms in tumor prevention and control, monoclonal IgEs of irrelevant specificity were loaded through biotin-avidin bridging onto tumor cells, either by systemic administration to tumor-bearing mice or pre-loading of tumor cells before inoculation. Here we show that systemic administration of biotinylated IgEs to mice bearing tumors pre-targeted with biotinylated antibodies and avidin significantly decreased tumor growth rate. In addition, as compared with IgG-loaded control cells, inoculation of suboptimal doses of IgE-loaded tumor cells suppressed tumor formation in a fraction of animals and induced protective host immunity by eliciting tumor-specific T-cell responses. Similarly, tumor vaccination experiments showed that irradiated tumor cells (IgE loaded by biotin-avidin bridging) conferred protective immunity at doses 100-fold lower than the corresponding control cells without IgE. Finally, in vivo depletion of eosinophils or T cells abrogated IgE-driven tumor growth inhibition. These results demonstrate that IgEs targeted on tumor cells not only possess a curative potential but also confer long-term antitumor immunity and that IgE-driven antitumor activity is not restricted to the activation of innate immunity effector mechanisms but also results from eosinophil-dependent priming of a T-cell-mediated adaptive immune response. This suggests a potential role for IgEs in the design of new cell-based tumor vaccines.

AB - Surface-bound IgE play a central role in antiparasite immunity; to exploit IgE-driven immune mechanisms in tumor prevention and control, monoclonal IgEs of irrelevant specificity were loaded through biotin-avidin bridging onto tumor cells, either by systemic administration to tumor-bearing mice or pre-loading of tumor cells before inoculation. Here we show that systemic administration of biotinylated IgEs to mice bearing tumors pre-targeted with biotinylated antibodies and avidin significantly decreased tumor growth rate. In addition, as compared with IgG-loaded control cells, inoculation of suboptimal doses of IgE-loaded tumor cells suppressed tumor formation in a fraction of animals and induced protective host immunity by eliciting tumor-specific T-cell responses. Similarly, tumor vaccination experiments showed that irradiated tumor cells (IgE loaded by biotin-avidin bridging) conferred protective immunity at doses 100-fold lower than the corresponding control cells without IgE. Finally, in vivo depletion of eosinophils or T cells abrogated IgE-driven tumor growth inhibition. These results demonstrate that IgEs targeted on tumor cells not only possess a curative potential but also confer long-term antitumor immunity and that IgE-driven antitumor activity is not restricted to the activation of innate immunity effector mechanisms but also results from eosinophil-dependent priming of a T-cell-mediated adaptive immune response. This suggests a potential role for IgEs in the design of new cell-based tumor vaccines.

UR - http://www.scopus.com/inward/record.url?scp=0035878749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035878749&partnerID=8YFLogxK

M3 - Article

C2 - 11454701

AN - SCOPUS:0035878749

VL - 61

SP - 5517

EP - 5522

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 14

ER -